Twincretin therapy for type 2 diabetes: how do two do?

Affiliations

¹ Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, SA, Australia; Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
² Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, SA, Australia; Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia. Electronic address: michael.horowitz@adelaide.edu.au.

Comment

Christopher K Rayner et al. Lancet. 2021.

. 2021 Aug 14;398(10300):560-561.

doi: 10.1016/S0140-6736(21)01597-X. Epub 2021 Aug 6.

¹ Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, SA, Australia; Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
² Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, SA, Australia; Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia. Electronic address: michael.horowitz@adelaide.edu.au.

No abstract available

Comment on

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Ludvik B, et al. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. Lancet. 2021. PMID: 34370970 Clinical Trial.